欢迎来到西安迈博睿(Mabioway)生物科技有限公司 Call: 15339069646 | E-mail: info@mabioway.cn 在线留言 |

服务热线

15339069646
网站导航
当前位置: 首页 > 产品展示 > 抗体产品 > 一抗 > 其他抗体
其他抗体

Anti-PCSK9 mAbs [3D2](MABL-2622)

简要描述:

Engineer antibody

产品参数:

Cat. No.:MABL-2622

Application:BLI, functional assay, inhibit, therapeutic, Block, ELISA

Isotype:Engineer antibody

Species Reactivity:Human

Clone No.:3D2

产品价格:¥0

详细介绍
Cat. No.
MABL-2622
Application
BLI, functional assay, inhibit, therapeutic, Block, ELISA
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
3D2
From
Recombinant Antibody
Specificity
This antibody binds PCSK9 and blocks the PCSK9-LDLR interaction in a dose-dependent manner with an IC50 of 2.25±1.23 nM (PMID: 33416098). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease enzyme encoded by the PCSK9 gene in humans and it plays a role in regulation of circulating cholesterol. It is associated with autosomal dominant hypercholesterolemia, a state of elevated levels of LDL (low-density lipoprotein) cholesterol. Autosomal dominant hypercholesterolemia can result in severe implications such as stroke and coronary heart disease.
Alternative Names
NARC1; NARC-1; PC9; Proprotein convertase subtilisin/kexin type; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9
UniProt
Q8NBP7
Immunogen
The original antibody was isolated from an scFv phage display library generated from blood, bone marrow, and cord blood samples from healthy donors by panning against recombinant PCSK9.
Application Notes
Indirect binding ELISA were performed to assess the specificity of this antibody against PCSK9. Biolayer interferometry analysis suggested that IgG1 version of this antibody had a binding affinity of 1.96±1.56X10−10 M towards PCSK9. In vitro, the PCSK9/low-density lipoprotein receptor (LDLR) pathway of Hep-G2 cells was inhibited by 3D2 treatment, thereby increasing LDL uptake in these cells. In addition, combination treatment with 3D2 and statin was more effective at increasing LDLR levels than treatment with 3D2 or statin alone. Furthermore, in mice treatment with this antibody resulted in a 3-fold increase in hepatic LDLR levels, and lowered total serum cholesterol by up to 61.5% in vivo (PMID: 33416098).
Antibody First Published
Dong et al. Construction and application of a human scFv phage display library based on Cre‑LoxP recombination for anti‑PCSK9 antibody selection. Int J Mol Med. 2021 Feb;47(2):708-718. PMID:33416098
Note on publication
Describes the generation of this antibody using phage display technology.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.

 


服务咨询

留言框

  • 标题:

  • 留言内容:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 详细地址:

推荐产品

联系我们

Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有

地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层

电话:15339069646 邮箱:info@mabioway.cn

陕ICP备2021006339号